SPONSOR

Yale University

Total Trials

Recruiting

Phases

EARLY_Phase 1, Phase 1, Phase 4, Phase 2, Phase 1, Phase 2

Conditions studied: Pain Substance Use Opioid Misuse Quality of Life Postpartum Hypertension Familial Alcoholism Vulnerability Speech Cannabis Opioid Use Disorder Alcohol Consumption

Yale University is a clinical research sponsor with 38 registered studies on ClinicalTrials.gov, of which 38 are actively recruiting participants. Research covers conditions including Pain, Substance Use, Opioid Misuse, Quality of Life.

The trial portfolio spans EARLY_Phase 1, Phase 1, Phase 4 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Yale University

How many clinical trials has Yale University sponsored?

ClinicalMetric currently tracks 38 clinical trials sponsored by Yale University, of which 38 are actively recruiting participants. These trials cover conditions including Pain, Substance Use, Opioid Misuse. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Yale University research focus on?

Yale University clinical trials span Pain, Substance Use, Opioid Misuse, Quality of Life, Postpartum Hypertension, and additional conditions. The research pipeline includes EARLY_Phase 1, Phase 1, Phase 4 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Yale University clinical trial?

To participate in a Yale University trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Yale University trials with current recruitment status updated daily.

Yale University

Frequently Asked Questions — Yale University

Clinical Trials by Yale University

M2VA Pain Care Pathway

Trauma-informed Approach to Timely Detection and Management of Early Postpartum Hypertension

Functional Neuroimaging of Alcoholism Vulnerability: Probing Glutamate and Reward, Using the mGluR5 Inhibitor Mavoglurant

Speech Motor Learning and Retention (Master Protocol)

Gender Related Differences in the Acute Effects of Delta-9-Tetrahydrocannabinol in Healthy Humans: Sub-Study I

Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment.

Influence of Mavoglurant on Alcohol Craving and Drinking in Heavy Drinkers

Promoting Alcohol Treatment Engagement Post-hospitalization

PK/PD of Oral and Vaporized Delta-9-Tetrahydrocannabinol (THC) in Older Adults

Modulating Temporoparietal Junction Mentalizing-Related Activity in Autism Spectrum Disorder (ASD) Using Transcranial Magnetic Stimulation (TMS)

T1CARE: A Trial of a Novel Intervention to Address Social Determinants of Health in Young Adults With Type 1 Diabetes

Imaging Traumatic Stress and Alcohol Use Disorder With [18F]Bavarostat

Ultrasound Effects on Glycemic Control in T2DM

The EXPLORE MG Registry for Myasthenia Gravis

Investigating the Mu:Kappa Opioid Receptor Imbalance in Alcohol Use Disorder

A Feasibility Study of Mass-Based Response Drug Screening to Guide Personalized Hyperthermic Intraperitoneal Chemotherapy for High-Grade Appendiceal and Colorectal Adenocarcinoma With Peritoneal Metastasis

Measuring Brain Health Using Low-Field Portable MRI

Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans

Affirmative Psychotherapy for Sexual Minority Women's Mental and Behavioral Health

Iadademstat + SBRT With Atezo in ES-SCLC

Hemodynamics Monitoring During Lower Body Negative Pressure (LBNP) Induced Controlled Hypovolemia

Combined THC and CBD for OUD and Chronic Pain

Reversibility of Brain Glucose Transport in Type 2 Diabetes Mellitus (T2DM)

AMPK-activation by Metformin in FSGS: AMP-FSGS

TRUsted rEsidents and Housing Assistance to Decrease Violence Exposure in New Haven

Recovery Finance: Financial Health and Mental Health After Incarceration

PRISM: Patient Experiences With PET Imaging in Prostate Cancer

Mechanisms of Diuretic Resistance in Heart Failure, Aim 1

OMAR Opioid Use Disorder

MDMA in Borderline Personality Disorder

HIV and Alcohol Research Center Focused on Polypharmacy (HARP) Pilot 2 (2nd HARP Pilot Intervention)

Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels

Effect of Empagliflozin on Peritoneal and Kidney Function in End Stage Renal Disease

Off-Label Medications for Alcohol Use Disorder Among Patients With HIV: Pilot Study 3 Semaglutide

Non-invasive Venous Pressure Estimation

Saci Nivo Rela for TNBC

Addressing Vaccine Acceptance in Carceral Settings Through Community Engagement

Intestinal Immunity in Neurologic Disease